EMEA-001261-PIP01-11-M07
Key facts
Invented name |
Halaven
|
Active substance |
Eribulin
|
Therapeutic area |
Oncology
|
Decision number |
P/0535/2021
|
PIP number |
EMEA-001261-PIP01-11-M07
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of soft tissue sarcoma
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Eisai Europe Ltd
Tel. +44 (0)20 8600 1400 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-001261-PIP01-11-M07
|
Compliance opinion date |
25/02/2022
|
Compliance outcome |
positive
|